Exact Sciences widens losses

Now that Exact Sciences Corp.’s Cologuard test for colorectal cancer is on the market, the company’s marketing budget has increased, and this contributed to a widened net loss for the third quarter ending Sept. 30. The company reported $32.2 million in operating expenses for the period, which included sales and marketing, research and development, and administrative costs.

The Madison-based company reported a net loss of $32.1 million (39 cents/share) in the third quarter, nearly triple its net loss of $11.2 million (16 cents/share) a year ago. Through September, the company had a net loss of $67.6 million (86 cents/share), compared to $34.3 million (52 cents/share) for the same period a year ago.